Salient Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-28,605
Closed -$2.35M 131
2017
Q2
$2.35M Sell
28,605
-19,800
-41% -$1.62M 0.05% 93
2017
Q1
$4.07M Sell
48,405
-4,330
-8% -$347K 0.07% 79
2016
Q4
$3.88M Sell
52,735
-111,698
-68% -$8.32M 0.07% 78
2016
Q3
$13.2M Sell
164,433
-8,981
-5% -$719K 0.27% 40
2016
Q2
$13.7M Sell
173,414
-6,241
-3% -$470K 0.3% 40
2016
Q1
$12.9M Buy
179,655
+26,512
+17% +$2.01M 0.37% 43
2015
Q4
$12.9M Buy
153,143
+12,678
+9% +$1.05M 0.34% 44
2015
Q3
$11.8M Buy
140,465
+6,101
+5% +$515K 0.29% 46
2015
Q2
$11.2M Buy
134,364
+4,250
+3% +$324K 0.21% 52
2015
Q1
$9.45M Buy
130,114
+17,912
+16% +$1.28M 0.18% 55
2014
Q4
$7.74M Buy
112,202
+17,894
+19% +$1.21M 0.15% 60
2014
Q3
$6.12M Buy
94,308
+20,926
+29% +$1.32M 0.11% 72
2014
Q2
$4.56M Buy
73,382
+22,551
+44% +$1.35M 0.1% 74
2014
Q1
$2.99M Buy
50,831
+32,863
+183% +$1.83M 0.08% 81
2013
Q4
$916K Buy
+17,968
New +$900K 0.03% 127

Other funds holding LLY

Salient Capital Advisors's LLY Position: Q3 2017 in Review

Salient Capital Advisors sold out of Eli Lilly (LLY) in Q3 2017, closing a stake of 28,605 shares — an estimated $2.35M sold.

Salient Capital Advisors first reported a position in LLY in Q4 2013 and held it in 15 quarters. The position peaked at $13.7M in Q2 2016. 1,229 funds tracked by Wall St. Rank hold LLY as of Q3 2017.

  • Salient Capital Advisors reported no remaining Eli Lilly position as of Q3 2017 after selling out during the quarter.
  • Salient Capital Advisors sold 28,605 Eli Lilly shares in Q3 2017, an estimated $2.35M.
  • Salient Capital Advisors first reported a position in Eli Lilly in Q4 2013 and held it in 15 quarters.
  • Salient Capital Advisors's Eli Lilly position peaked at $13.7M in Q2 2016.
  • 1,229 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2017.

Based on Salient Capital Advisors's 13F filing for Q3 2017, filed 6 Nov 2017.